MA41481A - Régime posologique pour un agoniste de récepteur s1p1 sélectif - Google Patents

Régime posologique pour un agoniste de récepteur s1p1 sélectif

Info

Publication number: MA41481A
Authority: MA; Morocco
Prior art keywords: selective; receptor agonist; dosage regime; regime; dosage
Prior art date: 2014-12-11

Application number

MA041481A

Other languages

English (en)

Other versions

MA41481B1 (fr

Inventor

Jasper Dingemanse

Matthias Hoch

Andreas Krause

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-11

Filing date

2015-12-09

Publication date

2017-12-19

2015-12-10 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2015-12-10 Priority claimed from PCT/EP2015/079208 external-priority patent/WO2016091996A1/fr

2017-12-19 Publication of MA41481A publication Critical patent/MA41481A/fr

2022-03-31 Publication of MA41481B1 publication Critical patent/MA41481B1/fr

Links

102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)

MA41481A 2014-12-11 2015-12-10 Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif MA41481B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2014077469		2014-12-11
PCT/EP2015/079208 WO2016091996A1 (fr)	2014-12-11	2015-12-10	Régime posologique pour un agoniste de récepteur s1p1 sélectif

Publications (2)

Publication Number	Publication Date
MA41481A true MA41481A (fr)	2017-12-19
MA41481B1 MA41481B1 (fr)	2022-03-31

Family

ID=54848562

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA41139A MA41139B1 (fr)	2014-12-11	2015-12-09	Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
MA41481A MA41481B1 (fr)	2014-12-11	2015-12-10	Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA41139A MA41139B1 (fr)	2014-12-11	2015-12-09	Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque

Country Status (25)

Country	Link
US (6)	US10245253B2 (fr)
EP (2)	EP3229794B1 (fr)
JP (3)	JP6437119B2 (fr)
KR (3)	KR20210122315A (fr)
CN (1)	CN106999462B (fr)
AU (1)	AU2015359306B2 (fr)
BR (1)	BR112017012396B1 (fr)
CA (1)	CA2964616C (fr)
CL (1)	CL2017001479A1 (fr)
CY (1)	CY2022011I2 (fr)
EA (2)	EA039629B1 (fr)
ES (1)	ES3053660T3 (fr)
HK (1)	HK1245106A1 (fr)
HR (1)	HRP20251463T1 (fr)
IL (2)	IL252701B (fr)
MA (2)	MA41139B1 (fr)
MX (2)	MX2021005516A (fr)
PH (1)	PH12017501060B1 (fr)
PL (1)	PL3229794T3 (fr)
RS (1)	RS67683B1 (fr)
SA (1)	SA517381489B1 (fr)
SG (1)	SG11201704569SA (fr)
SM (1)	SMT202500469T1 (fr)
UA (1)	UA122063C2 (fr)
WO (1)	WO2016092042A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2278960T5 (pl)	2008-03-17	2020-06-29	Actelion Pharmaceuticals Ltd.	Schemat dawkowania dla selektywnego agonisty receptora sip1
MA41139B1 (fr) *	2014-12-11	2026-02-27	Laboratoires Juvise Pharmaceuticals	Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
KR20200013086A (ko)	2014-12-11	2020-02-05	액테리온 파마슈티칼 리미티드	선택적 s1p1 수용체 효능제에 대한 투약 섭생
JOP20190207A1 (ar)	2017-03-14	2019-09-10	Actelion Pharmaceuticals Ltd	تركيبة صيدلانية تشتمل على بونيسيمود
US11014940B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en)	2018-10-16	2021-11-30	Celgene Corporation	Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms of a thiazolidinone compound, compositions and methods of use thereof
CA3182369A1 (fr) *	2020-05-06	2021-07-22	Imcyse Sa	Polytherapie pour le traitement de maladies associees au fumarate
WO2022223778A1 (fr) *	2021-04-23	2022-10-27	Helmholtz-Zentrum für Infektionsforschung GmbH	Acide citraconique et ses dérivés destinés à être utilisés en tant que médicament
KR20230120768A (ko)	2022-02-10	2023-08-17	하나 영농조합법인	양념 핫소스와 그 제조방법

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4959389A (en)	1987-10-19	1990-09-25	Speiser Peter P	Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19853487A1 (de)	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
GB0217152D0 (en)	2002-07-24	2002-09-04	Novartis Ag	Organic compounds
EP1646628A1 (fr)	2003-07-08	2006-04-19	Novartis AG	Composes benzenesulfonylamino, et compositions pharmaceutiques contenant ces composes
USRE43833E1 (en)	2003-11-21	2012-11-27	Actelion Pharmaceuticals Ltd.	Thiazolidin-4-one derivatives
USRE43728E1 (en)	2003-11-21	2012-10-09	Actelion Pharmaceuticals Ltd.	Thiazolidin-4-one derivatives
US7718704B2 (en)	2004-02-24	2010-05-18	Irm Llc	Immunosuppressant compounds and compositions
PL2316430T3 (pl) *	2004-10-08	2012-11-30	Forward Pharma As	Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
KR20070085465A (ko)	2004-11-29	2007-08-27	노파르티스 아게	Ｓ１ｐ 수용체 효능제의 투여 용법
US7879821B2 (en)	2006-01-26	2011-02-01	University Of Medicine And Dentistry Of New Jersey	Method for modulating inflammatory responses by altering plasma lipid levels
US8912340B2 (en)	2006-11-23	2014-12-16	Actelion Pharmaceuticals Ltd.	Process for the preparation of 2-imino-thiazolidin-4-one derivatives
TWI460166B (zh)	2006-11-23	2014-11-11	Actelion Pharmaceuticals Ltd	製備２-亞胺基-四氫噻唑-４-酮衍生物之新穎方法
EP2680010A1 (fr)	2007-02-08	2014-01-01	Biogen Idec MA Inc.	Essais de criblage de nrf2 et procédés et compositions correspondants
PL2278960T5 (pl)	2008-03-17	2020-06-29	Actelion Pharmaceuticals Ltd.	Schemat dawkowania dla selektywnego agonisty receptora sip1
RU2554347C2 (ru) *	2008-08-19	2015-06-27	Ксенопорт, Инк.	Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
EP2177521A1 (fr)	2008-10-14	2010-04-21	Almirall, S.A.	Nouveaux dérivés de 2-amidothiadiazole
GB0819182D0 (en)	2008-10-20	2008-11-26	Actelion Pharmaceuticals Ltd	Crystalline forms
US20100160369A1 (en)	2008-12-04	2010-06-24	Exelixis, Inc.	S1P1 Agonists and Methods of Making And Using
JP5657565B2 (ja)	2008-12-22	2015-01-21	ノバルティスアーゲー	Ｓ１ｐ受容体アゴニストの投与レジメン
TW201028143A (en)	2008-12-22	2010-08-01	Novartis Ag	Dosage regimen for a S1P receptor agonist
EP2202232A1 (fr)	2008-12-26	2010-06-30	Laboratorios Almirall, S.A.	Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
CN102369001A (zh)	2009-01-09	2012-03-07	前进制药公司	包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
EP2210890A1 (fr)	2009-01-19	2010-07-28	Almirall, S.A.	Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1
DE102010048788A1 (de)	2009-02-13	2011-05-19	Amw Gmbh	Transdermales System mit Immunmodulator
DE102009008851A1 (de)	2009-02-13	2010-08-19	Amw Gmbh	Transdermales System mit Immunmodulator
US20100260755A1 (en)	2009-04-09	2010-10-14	Medicinova, Inc.	Ibudilast and immunomodulators combination
EP2305660A1 (fr)	2009-09-25	2011-04-06	Almirall, S.A.	Nouveaux dérivés de thiadiazole
US20120238028A1 (en)	2009-12-01	2012-09-20	Metanomics Health Gmbh	Means and Methods for Diagnosing Multiple Sclerosis
EP2343287A1 (fr)	2009-12-10	2011-07-13	Almirall, S.A.	Nouveaux dérivés de 2-aminothiadiazole
DE102010026879A1 (de)	2010-02-11	2011-08-11	AMW GmbH, 83627	Transdermales System mit Immunmodulator
EP2366702A1 (fr)	2010-03-18	2011-09-21	Almirall, S.A.	Nouveaux dérivés d'oxadiazole
EP2390252A1 (fr)	2010-05-19	2011-11-30	Almirall, S.A.	Nouveaux dérivés de pyrazole
EP2455080A1 (fr)	2010-11-23	2012-05-23	Almirall, S.A.	Agonistes de récepteur S1P1 à utiliser dans le traitement de la sclérose en plaques
EP2713724A4 (fr)	2011-05-26	2015-03-11	Biogen Idec Inc	Méthodes de traitement de la sclérose en plaques et de conservation et/ou d'augmentation de la teneur en myéline
EP2715361A1 (fr)	2011-05-31	2014-04-09	Metanomics Health GmbH	Méthodes pour diagnostiquer la sclérose en plaques
CN114146081A (zh)	2012-02-07	2022-03-08	比奥根玛公司	含有富马酸二甲酯的药物组合物
US20130259856A1 (en)	2012-03-27	2013-10-03	Teva Pharmaceutical Industries, Ltd.	Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
US20130314669A1 (en)	2012-05-24	2013-11-28	Hadasit Medical Research Services And Development Ltd.	Method and system for assessing visual disorder
JP6324380B2 (ja)	2012-07-27	2018-05-16	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物
EP2692343A1 (fr)	2012-08-03	2014-02-05	Forward Pharma A/S	Polythérapie pour le traitement de la sclérose en plaques
EP2879674B1 (fr)	2012-08-06	2017-11-22	Biogen MA Inc.	Composés étant des agents de modulation de s1p et/ou des agents de modulation d'atx
US9499485B2 (en)	2012-08-06	2016-11-22	Biogen Ma Inc.	Compounds that are S1P modulating agents and/or ATX modulating agents
EP2883177A1 (fr)	2012-08-13	2015-06-17	Biogen Idec MA Inc.	Paramètres de progression de la maladie et leurs utilisations dans l'évaluation de la sclérose en plaques
SMT202000298T1 (it)	2012-08-17	2020-07-08	Actelion Pharmaceuticals Ltd	Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
CA2882730C (fr)	2012-08-22	2019-12-31	Arbor Pharmaceuticals, Llc	Formes de dosage orales de fumarate d'hydrogene methyle et promedicaments associes
US10945984B2 (en)	2012-08-22	2021-03-16	Arbor Pharmaceuticals, Llc	Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CA2887682A1 (fr)	2012-10-09	2014-04-17	Biogen Idec Ma Inc.	Polytherapies et leurs utilisations pour le traitement de troubles de la demyelinisation
WO2014071371A1 (fr) *	2012-11-05	2014-05-08	Xenoport, Inc.	Cocristaux de méthyl(2e)but-2-ène-1,4-dioate de (n,n‑diéthylcarbamoyl)méthyle
US8669281B1 (en)	2013-03-14	2014-03-11	Alkermes Pharma Ireland Limited	Prodrugs of fumarates and their use in treating various diseases
KR102085557B1 (ko)	2013-03-14	2020-03-06	엘커메스 파마 아일랜드 리미티드	푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
WO2015066515A1 (fr)	2013-11-01	2015-05-07	Receptos, Inc.	Modulateurs sélectifs des récepteurs de la sphingosine-1-phosphate et traitement combiné les utilisant
MA41139B1 (fr) *	2014-12-11	2026-02-27	Laboratoires Juvise Pharmaceuticals	Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
KR20200013086A (ko)	2014-12-11	2020-02-05	액테리온 파마슈티칼 리미티드	선택적 s1p1 수용체 효능제에 대한 투약 섭생

2015
- 2015-12-09 MA MA41139A patent/MA41139B1/fr unknown
- 2015-12-10 MA MA41481A patent/MA41481B1/fr unknown
- 2015-12-10 SG SG11201704569SA patent/SG11201704569SA/en unknown
- 2015-12-10 KR KR1020217030568A patent/KR20210122315A/ko not_active Ceased
- 2015-12-10 PL PL15808184.4T patent/PL3229794T3/pl unknown
- 2015-12-10 BR BR112017012396-7A patent/BR112017012396B1/pt active IP Right Grant
- 2015-12-10 RS RS20260077A patent/RS67683B1/sr unknown
- 2015-12-10 CN CN201580067625.2A patent/CN106999462B/zh active Active
- 2015-12-10 HR HRP20251463TT patent/HRP20251463T1/hr unknown
- 2015-12-10 UA UAA201707085A patent/UA122063C2/uk unknown
- 2015-12-10 EP EP15808184.4A patent/EP3229794B1/fr active Active
- 2015-12-10 KR KR1020177019100A patent/KR101996245B1/ko active Active
- 2015-12-10 MX MX2021005516A patent/MX2021005516A/es unknown
- 2015-12-10 EA EA201791260A patent/EA039629B1/ru unknown
- 2015-12-10 CA CA2964616A patent/CA2964616C/fr active Active
- 2015-12-10 WO PCT/EP2015/079311 patent/WO2016092042A1/fr not_active Ceased
- 2015-12-10 HK HK18104570.0A patent/HK1245106A1/zh unknown
- 2015-12-10 SM SM20250469T patent/SMT202500469T1/it unknown
- 2015-12-10 EA EA202290017A patent/EA202290017A1/ru unknown
- 2015-12-10 US US15/534,951 patent/US10245253B2/en active Active
- 2015-12-10 ES ES15808184T patent/ES3053660T3/es active Active
- 2015-12-10 KR KR1020197018384A patent/KR20190077131A/ko not_active Ceased
- 2015-12-10 MX MX2017007651A patent/MX382489B/es unknown
- 2015-12-10 JP JP2017531166A patent/JP6437119B2/ja active Active
- 2015-12-10 EP EP25194913.7A patent/EP4620526A3/fr active Pending
- 2015-12-10 AU AU2015359306A patent/AU2015359306B2/en active Active
2017
- 2017-05-09 SA SA517381489A patent/SA517381489B1/ar unknown
- 2017-06-06 IL IL252701A patent/IL252701B/en unknown
- 2017-06-07 PH PH12017501060A patent/PH12017501060B1/en unknown
- 2017-06-09 CL CL2017001479A patent/CL2017001479A1/es unknown
2018
- 2018-09-20 JP JP2018176173A patent/JP6846392B2/ja active Active
2019
- 2019-02-15 US US16/277,829 patent/US11026927B2/en active Active
2020
- 2020-12-23 JP JP2020213525A patent/JP7033642B2/ja active Active
2021
- 2021-05-20 US US17/325,912 patent/US11672783B2/en active Active
- 2021-12-12 IL IL288907A patent/IL288907A/en unknown
2022
- 2022-05-10 CY CY2022011C patent/CY2022011I2/el unknown
2023
- 2023-05-11 US US18/315,954 patent/US12409167B2/en active Active
2024
- 2024-01-02 US US18/401,886 patent/US20240131009A1/en not_active Abandoned
2025
- 2025-08-15 US US19/301,469 patent/US20250375426A1/en active Pending

Also Published As

Publication number	Publication date
JP6846392B2 (ja)	2021-03-24
BR112017012396A2 (pt)	2018-04-24
IL288907A (en)	2022-02-01
KR20170095302A (ko)	2017-08-22
MA41139B1 (fr)	2026-02-27
MX2017007651A (es)	2017-10-11
US20190175563A1 (en)	2019-06-13
MA41139A (fr)	2017-10-17
KR20190077131A (ko)	2019-07-02
US20210338640A1 (en)	2021-11-04
EP3229794C0 (fr)	2025-11-05
IL252701B (en)	2022-01-01
IL252701A0 (en)	2017-08-31
KR101996245B1 (ko)	2019-07-05
CA2964616A1 (fr)	2016-06-16
MX382489B (es)	2025-03-13
SG11201704569SA (en)	2017-07-28
US20240139160A1 (en)	2024-05-02
HRP20251463T1 (hr)	2026-01-16
EP3229794B1 (fr)	2025-11-05
US20170348287A1 (en)	2017-12-07
EA039629B1 (ru)	2022-02-18
UA122063C2 (uk)	2020-09-10
JP2019011343A (ja)	2019-01-24
EP3229794A1 (fr)	2017-10-18
US12409167B2 (en)	2025-09-09
CL2017001479A1 (es)	2018-02-09
SA517381489B1 (ar)	2022-03-13
EA201791260A1 (ru)	2017-10-31
MX2021005516A (es)	2022-09-27
US11672783B2 (en)	2023-06-13
US10245253B2 (en)	2019-04-02
US11026927B2 (en)	2021-06-08
JP7033642B2 (ja)	2022-03-10
RS67683B1 (sr)	2026-02-27
EP4620526A2 (fr)	2025-09-24
PH12017501060A1 (en)	2018-03-05
CY2022011I1 (el)	2022-07-22
JP6437119B2 (ja)	2018-12-12
ES3053660T3 (en)	2026-01-23
AU2015359306A1 (en)	2017-07-27
CY2022011I2 (el)	2022-07-22
EP4620526A3 (fr)	2025-12-10
WO2016092042A1 (fr)	2016-06-16
HK1245106A1 (zh)	2018-08-24
CA2964616C (fr)	2020-01-28
CN106999462A (zh)	2017-08-01
BR112017012396B1 (pt)	2023-12-12
JP2021059574A (ja)	2021-04-15
EA202290017A1 (ru)	2022-03-22
MA41481B1 (fr)	2022-03-31
US20250375426A1 (en)	2025-12-11
PL3229794T3 (pl)	2026-03-30
KR20210122315A (ko)	2021-10-08
CN106999462B (zh)	2020-10-23
AU2015359306B2 (en)	2020-07-23
SMT202500469T1 (it)	2026-01-12
PH12017501060B1 (en)	2022-03-25
JP2017537129A (ja)	2017-12-14
US20240131009A1 (en)	2024-04-25

Publication	Publication Date	Title
FR22C1021I2 (fr)	2023-04-14	Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif
CY2022011I2 (el)	2022-07-22	Δοσολογικο σχημα για την πονεσιμοδη, εναν επιλεκτικο αγωνιστη του υποδοχεα s1p1
IL276400A (en)	2020-09-30	Dopamine D3 receptor antagonist compounds
PT3593808T (pt)	2021-02-11	Polímeros de ligação a protões para administração oral
IL234638A0 (en)	2014-12-02	NMDA receptor antagonists for the treatment of Gaucher disease
PL3194670T3 (pl)	2022-06-06	Urządzenie do toalet
IL258606B (en)	2022-02-01	Dopamine d3 receptor antagonists with a morpholine complex
MA42309A (fr)	2021-03-24	Nouveau composé de tiacumicine pour régime posologique
HUE040508T2 (hu)	2019-03-28	Továbbfejlesztett takarmányadagoló szerkezet
FR3021675B1 (fr)	2017-05-26	Sachet-tiroir pour dejection canine
FR3031123B1 (fr)	2018-08-31	Montant pour cloison
GB201403942D0 (en)	2014-04-23	A dosing device
HK1248524A1 (en)	2018-10-19	Dosing regimen for a selective s1p1 receptor agonist
TH1601000316A (th)	2018-02-01	อะโกนิสต์ของตัวรับวาโซเพรสซิน-2
GB201419433D0 (en)	2014-12-17	Dopamine D3 receptor antagonist compounds
GB201419430D0 (en)	2014-12-17	Dopamine D3 receptor antagonist compounds
SMT201900247T1 (it)	2019-07-11	Imballo per un preservativo
UA30493S (uk)	2015-10-12	Упаковка для ліків «невролек»
GB201501974D0 (en)	2015-03-25	Network subscription for a new device
ES1104730Y (es)	2014-06-18	Dispositivo volteador para maquinas recreativas